Literature DB >> 25868519

The prion hypothesis of Parkinson's disease.

Yaping Chu1, Jeffrey H Kordower.   

Abstract

The discovery of alpha-synuclein's prion-like behaviors in mammals, as well as a non-Mendelian type of inheritance, has led to a new concept in biology, the "prion hypothesis" of Parkinson's disease. The misfolding and aggregation of alpha-synuclein (α-syn) within the nervous system occur in many neurodegenerative diseases including Parkinson's disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). The molecular basis of synucleinopathies appears to be tightly coupled to α-syn's conformational conversion and fibril formation. The pathological form of α-syn consists of oligomers and fibrils with rich in β-sheets. The conversion of its α-helical structure to the β-sheet rich fibril is a defining pathologic feature of α-syn. These kinds of disorders have been classified as protein misfolding diseases or proteopathies which share key biophysical and biochemical characteristics with prion diseases. In this review, we highlight α-syn's prion-like activities in PD and PD models, describe the idea of a prion-like mechanism contributing to PD pathology, and discuss several key molecules that can modulate the α-syn accumulation and propagation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25868519     DOI: 10.1007/s11910-015-0549-x

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  140 in total

1.  A novel cellular prion protein isoform present in rapid anterograde axonal transport.

Authors:  K Rodolfo; R Hässig; K L Moya; Y Frobert; J Grassi; L Di Giamberardino
Journal:  Neuroreport       Date:  1999-11-26       Impact factor: 1.837

Review 2.  Pathology associated with sporadic Parkinson's disease--where does it end?

Authors:  H Braak; C M Müller; U Rüb; H Ackermann; H Bratzke; R A I de Vos; K Del Tredici
Journal:  J Neural Transm Suppl       Date:  2006

3.  Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.

Authors:  He-Jin Lee; Ji-Eun Suk; Eun-Jin Bae; Jung-Ho Lee; Seung R Paik; Seung-Jae Lee
Journal:  Int J Biochem Cell Biol       Date:  2008-01-20       Impact factor: 5.085

Review 4.  Progress in defining the premotor phase of Parkinson's disease.

Authors:  Eduardo Tolosa; Claustre Pont-Sunyer
Journal:  J Neurol Sci       Date:  2011-06-15       Impact factor: 3.181

5.  Phosphorylated α-synuclein in Parkinson's disease.

Authors:  Yu Wang; Min Shi; Kathryn A Chung; Cyrus P Zabetian; James B Leverenz; Daniela Berg; Karin Srulijes; John Q Trojanowski; Virginia M-Y Lee; Andrew D Siderowf; Howard Hurtig; Irene Litvan; Mya C Schiess; Elaine R Peskind; Masami Masuda; Masato Hasegawa; Xiangmin Lin; Catherine Pan; Douglas Galasko; David S Goldstein; Poul Henning Jensen; Hui Yang; Kevin C Cain; Jing Zhang
Journal:  Sci Transl Med       Date:  2012-02-15       Impact factor: 17.956

6.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

7.  alpha-Synuclein and Parkinson disease susceptibility.

Authors:  S Winkler; J Hagenah; S Lincoln; M Heckman; K Haugarvoll; K Lohmann-Hedrich; V Kostic; M Farrer; C Klein
Journal:  Neurology       Date:  2007-09-13       Impact factor: 9.910

8.  Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.

Authors:  Kelvin C Luk; Cheng Song; Patrick O'Brien; Anna Stieber; Jonathan R Branch; Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-05       Impact factor: 11.205

9.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

10.  Caudo-rostral brain spreading of α-synuclein through vagal connections.

Authors:  Ayse Ulusoy; Raffaella Rusconi; Blanca I Pérez-Revuelta; Ruth E Musgrove; Michael Helwig; Bettina Winzen-Reichert; Donato A Di Monte
Journal:  EMBO Mol Med       Date:  2013-05-23       Impact factor: 12.137

View more
  30 in total

Review 1.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

2.  Survival and Progression in Synucleinopathy Phenotypes With Parkinsonism: A Population-Based Study.

Authors:  Rodolfo Savica; Pierpaolo Turcano; James H Bower; J Eric Ahlskog; Michelle M Mielke
Journal:  Mayo Clin Proc       Date:  2019-08-09       Impact factor: 7.616

3.  Cortical gray and subcortical white matter associations in Parkinson's disease.

Authors:  Nicholas W Sterling; Guangwei Du; Mechelle M Lewis; Steven Swavely; Lan Kong; Martin Styner; Xuemei Huang
Journal:  Neurobiol Aging       Date:  2016-09-28       Impact factor: 4.673

4.  Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.

Authors:  P A Broderick; L Wenning; Y-S Li
Journal:  J Neural Transm (Vienna)       Date:  2016-10-28       Impact factor: 3.575

Review 5.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

6.  A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease.

Authors:  Lasse Pihlstrøm; Cornelis Blauwendraat; Chiara Cappelletti; Victoria Berge-Seidl; Margrete Langmyhr; Sandra Pilar Henriksen; Wilma D J van de Berg; J Raphael Gibbs; Mark R Cookson; Andrew B Singleton; Mike A Nalls; Mathias Toft
Journal:  Ann Neurol       Date:  2018-08-26       Impact factor: 10.422

Review 7.  α-Synuclein and nonhuman primate models of Parkinson's disease.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  J Neurosci Methods       Date:  2015-08-03       Impact factor: 2.390

8.  Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.

Authors:  Negin Nouraei; Daniel M Mason; Kristin M Miner; Michael A Carcella; Tarun N Bhatia; Benjamin K Dumm; Dishaben Soni; David A Johnson; Kelvin C Luk; Rehana K Leak
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

9.  Nonhuman Primate Models of Neurodegenerative Disorders.

Authors:  Marina E Emborg
Journal:  ILAR J       Date:  2017-12-01

Review 10.  Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.

Authors:  Esteban Luna; Kelvin C Luk
Journal:  FEBS Lett       Date:  2015-10-23       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.